In May 2019, based on results of a phase 3 trial (IMpassion 130), the FDA approved the use of atezolizumab in combination with paclitaxel protein-bound for the treatment of patients with PD-L1+ (ie, ≥1% expression by tumor immune cells) triple-negative breast cancer (TNBC)57. The gene discussed is CD274; the disease is neoplasm.